Drug intelligence / Profile preview

9-valent HPV recombinant vaccine

Development stage: Phase 1
Lead developer: Shanghai Bovax Biotechnology
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The 9-valent HPV recombinant vaccine is a vaccine designed to protect against nine types of Human Papillomavirus (HPV): types 6, 11, 16, 18, 31, 33, 45, 52, and 58. It is produced in *Hansenula Polymorpha* and developed by Shanghai Bovax Biotechnology Co., Ltd. The vaccine aims to prevent HPV-related diseases, including various cancers and precancerous lesions such as cervical cancer, vulvar cancer, vaginal cancer, oropharyngeal cancer, genital warts, and intraepithelial neoplasias.

Other names: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)

Targets

HPV L1 (Human papillomavirus L1 capsid protein)

Beyond the preview

Go deeper on 9-valent HPV recombinant vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 9-valent HPV recombinant vaccine.

Explore the full profile